Sean Gill

Sean Gill is currently a Principal Clinical Scientist at CSL, where they contribute to the scientific development of clinical programs, including HEMGENIX. Previously, they held various roles in clinical project management and development, including positions at Chemomab Therapeutics, CSL Behring, and Spark Therapeutics. With a strong background in clinical trials and operational planning, Sean has worked on both early-stage clinical studies and the management of global trials for major pharmaceutical companies. They earned a B.S. in Microbiology from the University of Pittsburgh and are pursuing a Master of Arts in Cellular Biology at Villanova University.